Tumor markers Predicting Lymph Node Metastases in Endometrial Carcinoma
- Prosjektnummer
- 911069
- Ansvarlig person
- Ingeborg Bø Engelsen
- Institusjon
- Helse Bergen HF
- Prosjektkategori
- Forskerutdanning - dr.grad
- Helsekategori
- Oncogenesis & Cancer Research
- Forskningsaktivitet
- Klinisk forskning
HER-2/neu expression is associated with high tumor cell proliferation and aggressive phenotype in a population based patient series of endometrial carcinomas.
Int J Oncol 2008 Feb;32(2):307-16.
PMID: 18202752
GATA3 expression in estrogen receptor alpha-negative endometrial carcinomas identifies aggressive tumors with high proliferation and poor patient survival.
Am J Obstet Gynecol 2008 Nov;199(5):543.e1-7. Epub 2008 jul 3
PMID: 18599012
Low BMI-1 expression is associated with an activated BMI-1-driven signature, vascular invasion, and hormone receptor loss in endometrial carcinoma.
Br J Cancer 2008 May;98(10):1662-9. Epub 2008 mai 13
PMID: 18475299
Pathologic expression of p53 or p16 in preoperative curettage specimens identifies high-risk endometrial carcinomas.
Am J Obstet Gynecol 2006 Oct;195(4):979-86. Epub 2006 mai 3
PMID: 16677592
HER-2/neu expression is associated with high tumor cell proliferation and aggressive phenotype in a population based patient ser
Poster AACR 2007
Kan tumormarkører identifisere pasienter for utprøving av ny målrettet terapi ved endometriecancer?
Norwegian Gynecological society, Oslo 2006. Oral presentation. Abstract published in Gynekologen Nr.3 2006.
HER-2/neu expression is associated with increased tumor cell proliferation, loss of hormone receptors and an aggressive phenotyp
Submitted to Clinical cancer research dec. 2006
Gene expression profiles identify an aggressiv phenotype in endometrial carcinoma
American Association for Cancer Research Annual meeting, Washington DC, april 2006
Gen ekspresjonsprofil identifiserer aggressiv fenotype ved endometriecancer.
Norwegian Gynecological society, Oslo 2006. Oral presentation. Abstract published in Gynekologen Nr.3 2006.
Biologic and prognostic markers in endometrial carcinoma. A study with special focus on tumor markers in curettage specimens.
- Disputert:
- juni 2008
- Hovedveileder:
- Helga Salvesen
eRapport er utarbeidet av Sølvi Lerfald og Reidar Thorstensen, Regionalt kompetansesenter for klinisk forskning, Helse Vest RHF, og videreutvikles av de fire RHF-ene i fellesskap, med støtte fra Helse Vest IKT
Alle henvendelser rettes til Faglig rapportering, Helse Vest